Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Boni · SciRah

Researcher profile · Semantic Scholar

V. Boni

Share profile

V. Boni — researcher profile on SciRah

h-index: 38
Works: 293
Citations: 9,159

Most-cited papers

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
A. Oaknin, L. Gilbert, A. Tinker, Jubilee Brown +18 more
2022Journal for ImmunoTherapy of Cancer307 citations Open access
Semantic Scholar
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors
Thierry André, D. Berton, G. Curigliano, R. Sabatier +23 more
2023JAMA Network Open121 citations Open access
Semantic Scholar
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
A. Oaknin, B. Pothuri, L. Gilbert, R. Sabatier +17 more
2023Clinical Cancer Research82 citations Open access
Semantic Scholar
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
A. Oaknin, K. Moore, T. Meyer, J. L. López-Picazo González +16 more
2024The Lancet Oncology60 citations
Semantic Scholar
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
V. Boni, M. Fidler, H. Arkenau, A. Spira +24 more
2022Clinical Cancer Research58 citations Open access
Semantic Scholar
Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment
P. Jänne, Frédéric Bigot, K. Papadopoulos, Lauriane Eberst +24 more
2023Molecular Cancer Therapeutics52 citations
Semantic Scholar
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, N. Turner, C. Barrios, S. Isakoff +24 more
2023Clinical Cancer Research50 citations Open access
Semantic Scholar
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
S. Weiss, M. Sznol, M. Shaheen, M. Berciano-Guerrero +13 more
2023Clinical Cancer Research44 citations Open access
Semantic Scholar
First-in-human dose escalation study of cyclin-dependent kinase-9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy.
J. Diamond, V. Boni, Emerson Lim, G. Nowakowski +13 more
2022Clinical Cancer Research36 citations Open access
Semantic Scholar
Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
U. Vaishampayan, P. Tomczak, J. Muzaffar, I. Winer +16 more
2022Journal of Clinical Oncology34 citations
Semantic Scholar
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
S. Kopetz, V. Boni, Ken Kato, K. Raghav +9 more
2025Nature Medicine32 citations Open access
Semantic Scholar
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
U. Vaishampayan, J. Muzaffar, I. Winer, S. Rosen +16 more
2024Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
K. Jhaveri, M. Bellet, N. Turner, S. Loi +18 more
2023Clinical Cancer Research22 citations Open access
Semantic Scholar
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
A. Leary, A. Oaknin, J. Trigo, V. Moreno +9 more
2023European Journal of Cancer15 citations Open access
Semantic Scholar
Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).
H. R. Kim, Omar Saavedra, A. Cervantes, I. Lugowska +16 more
2024Journal of Clinical Oncology12 citations
Semantic Scholar
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
P. Grivas, E. Garralda, F. Meric-Bernstam, I. Mellinghoff +37 more
2024Clinical Cancer Research11 citations Open access
Semantic Scholar
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
S. Hernandez, E. Conde, Aida Molero, A. Suárez-Gauthier +17 more
2023Archives of Pathology & Laboratory Medicine11 citations Open access
Semantic Scholar
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC)
N. Turner, S. Loi, H. Moore, Ching-Wei Chang +6 more
2022Cancer Research11 citations
Semantic Scholar
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
K. Yonemori, V. Boni, K. Min, T. Meniawy +20 more
2024Gynecologic Oncology10 citations Open access
Semantic Scholar
A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
P. Aftimos, M. Oliveira, K. Punie, V. Boni +16 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).
J. de Bono, M. D. Fenor de la Maza, V. Boni, J. Mateo +11 more
2026Journal of Clinical Oncology7 citations
Semantic Scholar
Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)
S. Modi, T. Yap, T. Tan, A. Santoro +38 more
2025Cancer Research7 citations
Semantic Scholar
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).
S. Kopetz, V. Boni, K. Kato, K. Raghav +5 more
2024Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
K. Jhaveri, Haeseong Park, J. Waisman, J. Goldman +15 more
2022Cancer Research7 citations
Semantic Scholar
Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study
A. Oaknin, William McKean, M. V. van Dongen, I. Ray-Coquard +16 more
2026Gynecologic Oncology6 citations
Semantic Scholar
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial
E. Calvo, V. Boni, Olivier Dumas, S. Shin +6 more
2025Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors
L. Siu, E. Cabanas, V. Boni, A. Tolcher +10 more
2024Cancer Research6 citations
Semantic Scholar
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.
E. Garralda, Arjun Oberoi, G. de Velasco, Ivan Victoria +15 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer
S. Chandarlapaty, H. Linden, P. Neven, K. Petráková +12 more
2022Cancer Research6 citations
Semantic Scholar
Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
K. Miller, S. Tolaney, L. Emens, Sung-Bae Kim +11 more
2023Cancer Research5 citations
Semantic Scholar
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer
R. Olivera-Salguero, E. Seguí, J. Cejalvo, M. Oliveira +30 more
2023Frontiers in Oncology5 citations Open access
Semantic Scholar
Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.
H. R. Kim, Arjun Oberoi, Juanita S. Lopez, A. El-Khoueiry +16 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
T. van Gorp, A. González-Martín, Shiraj Sen, J. Sehouli +14 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer
W. McKean, P. Bedard, P. Dinh, D. Sabanathan +20 more
2025Cancer Research4 citations
Semantic Scholar
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
J. de Bono, Anja Williams, I. Melero, A. Jayaram +25 more
2025Clinical Cancer Research4 citations Open access
Semantic Scholar
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
P. Giannatempo, M. Galsky, Ignacio Durán, V. Boni +9 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Abstract 5135: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
T. André, Susana Banerjee, D. Berton, S. Ellard +8 more
2022Cancer Research4 citations
Semantic Scholar
Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)
S. Hurvitz, V. Boni, E. Comen, S. Im +15 more
2022Cancer Research4 citations
Semantic Scholar
Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.
E. Calvo, V. Boni, A. Chaudhry, P. Debruyne +8 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Abstract P4-10-21: Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer (TNBC) patients (pts) with NECTIN4 gene amplification (amp)
N. Klümper, Viktor Grünwald, J. Brägelmann, M. McKean +19 more
2025Clinical Cancer Research3 citations
Semantic Scholar
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
A. Hansen, Alison Y. Zhang, V. Boni, C. Mantia +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC).
T. van Gorp, J. Sehouli, D. Richardson, R. Kristeleit +10 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A -mutated ovarian clear cell carcinoma or endometrial carcinoma.
L. Duska, Kalyan Banda, A. Oaknin, V. Ribrag +16 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies
Bob T. Li, L. Gandhi, Vignesh Ravichandran, B. Besse +21 more
2025Clinical Lung Cancer2 citations
Semantic Scholar
Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.
S. Kopetz, R. García-Carbonero, Sae-Won Han, I. Rodriguez Rivera +9 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2- breast cancer.
Hyo Han, Patricia M. LoRusso, E. Hamilton, N. Martínez-Jáñez +9 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Jacqueline H. Starrett, Eric L Allen, Melissa Neal, Samhita Iyer +11 more
2025Molecular Cancer Therapeutics2 citations Open access
Semantic Scholar
Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors.
A. Tolcher, L. Siu, E. Garralda-Cabanas, V. Boni +11 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i
A. Patnaik, S. A. Novoa, M. Bellet-Ezquerra, F. Bidard +17 more
2024Cancer Research2 citations
Semantic Scholar
A Plain Language Summary of Results from the GARNET Study of Dostarlimab in Patients with Endometrial Cancer.
A. Oaknin, L. Gilbert, A. Tinker, Jubilee Brown +14 more
2023Future Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Oaknin×9
Invite
A. Oaknin — researcher profile on SciRah
R. Kristeleit×6
Invite
R. Kristeleit — researcher profile on SciRah
J. Veneris×6
Invite
J. Veneris — researcher profile on SciRah
L. Gilbert×5
Invite
L. Gilbert — researcher profile on SciRah

×4

Invite

V. Samouëlian — researcher profile on SciRah

Invite

V. Moreno — researcher profile on SciRah

Invite

A. Italiano — researcher profile on SciRah

Invite

S. Rosen — researcher profile on SciRah

Invite

K. Jhaveri — researcher profile on SciRah

Invite

S. Loi — researcher profile on SciRah

Omar Saavedra×4

Invite

Omar Saavedra — researcher profile on SciRah

A. Cervantes×4

Invite

A. Cervantes — researcher profile on SciRah